On 4/19/2017, Shares of Depomed, Inc. (NASDAQ:DEPO) closed at $11.87 in last trading day. After noting the initial trading entry at $12.06, it reached to a day’s high of $12.12 and moved to a day’s low of $11.85. The recent daily volume was 1.3 million as contrast to it’s an average volume of 1.59 million.
The last close of the Depomed, Inc. stock reflects that it traded -16.71% from its 50-day moving average of $14.25. The stock traded below -35.84% to its 200-day MA of $18.50. Furthermore, it moved lower -56.07% from its 52-week high of $27.02 and +0.34% up from $11.83, which is 52-week low of the stock.
During the last month, Depomed, Inc.’s (DEPO) has changed -24.63% and performed -50.19% over the last 6 months. The mean rating score for this stock is at 2.50. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 4.84% in recent month and observed Weekly Volatility of 3.22%.
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. The company sells its products to wholesalers and retail pharmacies. It also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Innoviva, Inc (NASDAQ:INVA) finalized the last transaction at value of $14.02, with a daily change of +0.65% or +0.09 points. The company maintained volume of 1.13 million shares. In past trading day, the stock hit the maximum price of $14.17 and touched to minimum value of $13.87. It has a market cap of $ 1.53B.
As of last trade close, the stock is trading downside -3.64% from its one year high of $14.55 and moved +61.71% upward from $8.67, which is one year low of the stock.
The stock traded above +6.73% from its 50-day moving average of $13.14. Furthermore, the stock moved up +23.28% to its 200-day MA of $ 11.37.
Innoviva, Inc.’s (INVA) moved with shift of -2.77% in the past week. Over the last three months, the shares of the company have changed 29.10% and performed 40.48% over the last six months. The stock currently has Monthly Volatility of 3.41% and Weekly Volatility of 2.25%.
Innoviva, Inc. engages in the development and commercialization of bio-pharmaceuticals. Its portfolio of respiratory products include RELVAR/BREO ELLIPTA, (fluticasone furoate/ vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI). The company, under its the Long-Acting Beta2 Agonist (LABA) collaboration agreement and the strategic alliance agreement with Glaxo Group Limited (GSK), is entitled to receive royalties on the sales of RELVAR/BREO ELLIPTA; and a 15% of any future payments made by GSK under its agreements relating to the combination FF/UMEC/VI and the Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy and in combination with other therapeutically active components. It has LABA collaboration agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was founded in 1996 and is headquartered in Brisbane, California.